• The document is a transcript of a post-results earnings conference call held on August 4, 2026, following the company's Q1 FY27 results announcement.
  • The conference call was held at an unspecified time (referred to as "good evening" in the transcript) and was specifically for analysts and institutional investors.
  • The stated purpose of the event was to discuss Alembic Pharmaceuticals' performance for the quarter ended June 30, 2026 (Q1 FY27), including business performance, strategic developments, and outlook.
  • Management participants included:
  • Mr. Pranav Amin, Managing Director
  • Mr. G. Krishnan, Chief Financial Officer
  • Ms. Isha Lamba, Head, Investor Relations and Corporate Development
  • Other unspecified members of management
  • The company did not indicate whether a presentation, earnings deck, transcript, or recording would be made available, though this transcript was subsequently filed with the exchanges.
  • The company included standard forward-looking statement disclaimers, noting that statements were based on management's current expectations and subject to risks and uncertainties that may cause actual results to differ materially.

Financial Highlights Discussed

  • Q1 FY27 Financial Performance:
  • Consolidated revenue: INR2,150 crores, up 26% YoY
  • EBITDA: INR348 crores, up 21% YoY
  • EBITDA margin: 16%
  • Profit before tax: INR223 crores, up 17% YoY
  • Profit after tax: INR173 crores, up 12% YoY
  • Effective tax rate: 22% (vs. 19% in Q1 FY26)
  • Business Segment Performance:
  • India Branded business: 7% growth
  • International Generics: 37% growth
  • US Generics: 49% growth
  • API business: 33% growth
  • Animal Health division: 24% growth
  • R&D Investment: INR186 crores (9% of revenue), focused on peptide development, exhibit batches, regulatory filings, and portfolio development.
  • Operational Metrics:
  • Launched 7 products in US market
  • Filed 4 ANDAs
  • Received 10 approvals
  • Expecting 15 more launches in remainder of FY27
  • Guidance Updates:
  • Upgraded overall FY27 growth outlook from low double-digits to mid-teens
  • US Generics growth expectation upgraded from low-to-mid teens to mid-to-high teens
  • Other businesses maintain previous guidance
  • EBITDA margin guidance maintained with 150 bps dilution from US branded business investments
  • Expect US branded business to start contributing positively next financial year (FY28)

Additional Notes Section

  • The document is a complete transcript of the earnings conference call, including management presentations and Q&A session with analysts from HSBC, DSP Mutual Funds, IIFL Securities, Dolat Capital, Motilal Oswal, Bank of Baroda Capital Markets, and others.
  • The transcript contains detailed financial data and forward-looking statements about the company's performance and outlook.
  • The conference call was referenced as a follow-up to the company's intimation dated July 27, 2026, and this transcript was submitted to the stock exchanges on August 10, 2026.